188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer
188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer. // EANM Innovation. – URL: https://www.sciencedirect.com/science/article/pii/S3051291326002880?dgcid=rss_sd_all
188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer. EANM Innovation. https://www.sciencedirect.com/science/article/pii/S3051291326002880?dgcid=rss_sd_all
“188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer.” EANM Innovation.
@article{article89005,
title = {188Rhenium skin cancer therapy: Two–year efficacy, safety and patient reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer},
journal = {EANM Innovation},
url = {https://www.sciencedirect.com/science/article/pii/S3051291326002880?dgcid=rss_sd_all}
}